Morgan Stanley Downgrades BioMed Realty (BMR) to Equalweight
Tweet
Share
E-mailGet Alerts BMR Hot Sheet
Price: $1.32 +3.94%
Rating Summary:
6 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
6 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Morgan Stanley downgraded BioMed Realty (NYSE: BMR) from Overweight to Equalweight, price target cut $1 to $20.
For an analyst ratings summary and ratings history on BioMed Realty click here. For more ratings news on BioMed Realty click here.
Shares of BioMed Realty closed at $18.14 yesterday.
For an analyst ratings summary and ratings history on BioMed Realty click here. For more ratings news on BioMed Realty click here.
Shares of BioMed Realty closed at $18.14 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Beamr reports 17% revenue drop, widens loss in first half 2026
- Wolfe Research Downgrades T-Mobile (TMUS) to Peerperform
- Beamr Issues Q2-2026 CEO Letter to Shareholders: Expanding Our Reach into Autonomous Vehicle Teams
Create E-mail Alert Related Categories
DowngradesRelated Entities
Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
